Article Text

PDF
O08-3 Aryl hydrocarbon receptor (AHR) activation and risk of lymphoma subtypes
  1. Pierluigi Cocco1,
  2. Maria Grazia Ennas1,
  3. Mariagrazia Zucca1,
  4. Sonia Sanna1,
  5. Marina Padoan2,
  6. Angela Gambelunghe3,
  7. Aldo Scarpa4,
  8. Giovanni Maria Ferri5,
  9. Lucia Miligi6,
  10. Simonetta Di Lollo6,
  11. Giacomo Muzi3,
  12. Corrado Magnani2,
  13. Marcello Campagna1
  1. 1University of Cagliari, Monserrato, Italy
  2. 2University of East Piedmont, Novara, Italy
  3. 3University of Perugia, Perugia, Italy
  4. 4University of Verona, Verona, Italy
  5. 5University of Bari, Bari, Italy
  6. 6University of Florence, Florence, Italy

Abstract

Objective Dioxin, a known risk factor for lymphoma, and numerous other xenobiotics, induce their own metabolism by initially activating the aryl hydrocarbon receptor (AhR). We used the serum samples of participants to the multicentre Italian study on gene-environment interactions in lymphoma aetiology (ITGxE) to explore AhR activation as an intermediate step in dioxin-induced risk of lymphoma, and particularly B-cell lymphoma subtypes.

Methods Overall, serum samples of 343 lymphoma cases and 1899 population and hospital controls from five Italian areas (Florence, Bari, Perugia, Novara, and central and southern Sardinia) were available for study. A 50 microliter serum aliquot of each study participant potentially carrying the AhR activator, was added to HepG2 cells, transfected with specific reporter systems including the DRE specific AhR activating sequence upstream to the luciferase reported gene. The intensity of light generated by the Dual-Luciferase Assay, captured with a luminometer, is directly correlated with the concentration and potency of the inducing xenobiotic. Risk of lymphoma overall and by its major B-cell specific subtypes associated with AhR activation positivity as a binary outcome was calculated using an unconditional logistic regression model adjusted by age and gender.

Results Among the B-cell lymphoma subtypes, there was a significant two-fold excess risk for follicular lymphoma (OR = 2.0, 95% CI: 1.0, 4.0) and chronic lymphocytic leukaemia (OR = 2.3, 95% CI: 1.0, 5.0). No increase in risk associated with AhR positivity was observed for the other B-cell lymphoma subtypes we tested, namely diffuse large B-cell lymphoma, and multiple myeloma, nor for Hodgkin lymphoma.

Conclusions Our results show that the Dual-Luciferase Assay is a reliable and inexpensive test to detect AhR activation and its role in lymphomagenesis.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.